Baidu
map

Cell Metab:意外!肥胖易增加糖尿病风险,背后有个关键分子

2018-10-17 悠然 生物探索

10月11日,《Cell Metabolism》期刊新发表了这一篇题为“Protein Kinase C Epsilon Deletion in Adipose Tissue, but Not in Liver, Improves Glucose Tolerance”的文章,揭示了一种关键酶——蛋白激酶C ε(protein kinase C epsilon,PKCε)在糖尿病中的代谢细节。这一研


https://doi.org/10.1016/j.cmet.2018.09.013

10月11日,《Cell Metabolism》期刊新发表了这一篇题为“Protein Kinase C Epsilon Deletion in Adipose Tissue, but Not in Liver, Improves Glucose Tolerance”的文章,揭示了一种关键酶——蛋白激酶C ε(protein kinase C epsilon,PKCε)在糖尿病中的代谢细节。这一研究由澳大利亚Garvan医学研究所的副教授Carsten Schmitz-Peiffer及其团队完成。

一个惊人发现

PKCε是一种细胞质酶,调控糖代谢。过去的研究认为,PKCε在肝脏组织中活跃,通过磷酸化胰岛素受体抑制胰岛素。

然而,最新研究却揭示,这一促成糖尿病的关键分子主要来源并不是于肝脏或者胰腺

通常,科学家们会使用高脂肪饮食(HFD)诱导小鼠发生2型糖尿病,促使大多数小鼠变得“葡萄糖不耐受”——进食后无法控制血糖。特别是,肝脏变得“胰岛素抵抗”——不再对胰岛素积极响应。

10年前,Carsten Schmitz-Peiffer发现PKCε对糖尿病的发展很重要。他们证实,完全不表达PKCε的突变小鼠不会发生类似于糖尿病的症状,即便它们处于其他正常小鼠易患糖尿病的环境中。

“我们发现,完全不表达PKCε的小鼠即便食用高脂肪食物,也不会发生葡萄糖不耐症(glucose intolerant)。”Carsten Schmitz-Peiffer表示道。

让他们意外的是,当去除肝脏中表达的PKCε,这些突变小鼠并未按照过去的理论那样不发生糖尿病。在最新的研究中,这些突变小鼠高在脂肪喂食之后竟然出现了血糖不耐症。

一个新的答案:脂肪

如果不是肝脏,那么PKCε是在哪里促成葡萄糖不耐症?

最新研究发现,当将脂肪组织中产生的PKCε完全清除,小鼠则不会发生葡萄糖不耐症。这意味着,PKCε促成糖尿病的工作场所并不是肝脏,而是在脂肪组织。

PKCε在多个组织中都有表达,但是,最新研究赋予了脂肪组织一个新功能,也进一步解析了肥胖与糖尿病高风险之间关联的原因。


PKCε的工作细节(图片来源:Cell Metabolism)

变化

最新研究发现,当存在和缺乏PKCε时,脂肪细胞在形状和大小上会表现出差异。

“在显微镜下,脂肪细胞会非常不同。” Carsten Schmitz-Peiffer表示道,“当脂肪组织不表达PKCε时,高脂肪喂食的小鼠脂肪细胞大部分都较小且健康。相反,表达PKCε的高脂肪喂食小鼠(伴随有葡萄糖不耐症),其脂肪细胞多是不健康、肿胀的,很难获得氧气且容易发炎。”

Carsten Schmitz-Peiffer认为,这一变化可能会对糖尿病产生广泛而复杂的影响。“我们知道,脂肪组织不仅仅储存脂肪。”他解释说,“它是非常活跃的器官,释放许多信号/分子至身体其他的组织。PKCε影响脂肪细胞的健康,这意味着它会进一步改变脂肪细胞传递的信号、释放的分子,后者会在肝脏等器官组织中发挥作用,进而干扰葡萄糖代谢。”

抑制PKCε

这一最新研究为通过靶向PKCε治疗糖尿病的药物开发提供了新的线索。Schmitz-Peiffer教授正和Monash医药研究所的Ray Norton教授、Jonathan Baell教授合作,基于药物研发平台开发一种口服多肽,用于抑制PKCε的活性。

原始出处:

Amanda E. Brandon, Bing M. Liao, Barbara Diakanastasis, et.al.  Protein Kinase C Epsilon Deletion in Adipose Tissue, but Not in Liver, Improves Glucose Tolerance. Cell Metabolism October 11, 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961203, encodeId=11e019612034e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 27 17:13:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870931, encodeId=e8ff18e0931b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 21 16:13:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896397, encodeId=ab90189639e79, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 13 18:13:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887948, encodeId=db22188e948e0, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 23 13:13:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349716, encodeId=9011349e161b, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Oct 18 07:27:01 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041917, encodeId=ced6104191ebf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 17 16:13:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2019-02-27 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1961203, encodeId=11e019612034e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 27 17:13:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870931, encodeId=e8ff18e0931b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 21 16:13:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896397, encodeId=ab90189639e79, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 13 18:13:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887948, encodeId=db22188e948e0, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 23 13:13:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349716, encodeId=9011349e161b, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Oct 18 07:27:01 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041917, encodeId=ced6104191ebf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 17 16:13:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2019-03-21 hb2008ye
  3. [GetPortalCommentsPageByObjectIdResponse(id=1961203, encodeId=11e019612034e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 27 17:13:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870931, encodeId=e8ff18e0931b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 21 16:13:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896397, encodeId=ab90189639e79, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 13 18:13:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887948, encodeId=db22188e948e0, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 23 13:13:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349716, encodeId=9011349e161b, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Oct 18 07:27:01 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041917, encodeId=ced6104191ebf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 17 16:13:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2019-06-13 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1961203, encodeId=11e019612034e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 27 17:13:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870931, encodeId=e8ff18e0931b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 21 16:13:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896397, encodeId=ab90189639e79, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 13 18:13:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887948, encodeId=db22188e948e0, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 23 13:13:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349716, encodeId=9011349e161b, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Oct 18 07:27:01 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041917, encodeId=ced6104191ebf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 17 16:13:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-23 guojianrong
  5. [GetPortalCommentsPageByObjectIdResponse(id=1961203, encodeId=11e019612034e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 27 17:13:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870931, encodeId=e8ff18e0931b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 21 16:13:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896397, encodeId=ab90189639e79, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 13 18:13:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887948, encodeId=db22188e948e0, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 23 13:13:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349716, encodeId=9011349e161b, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Oct 18 07:27:01 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041917, encodeId=ced6104191ebf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 17 16:13:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-18 kafei

    学习了谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1961203, encodeId=11e019612034e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 27 17:13:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870931, encodeId=e8ff18e0931b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 21 16:13:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896397, encodeId=ab90189639e79, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 13 18:13:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887948, encodeId=db22188e948e0, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 23 13:13:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349716, encodeId=9011349e161b, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Oct 18 07:27:01 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041917, encodeId=ced6104191ebf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 17 16:13:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-17 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

PNAS:教育可以减少与遗传性肥胖相关的健康差异

最近,来自南加州大学和麻省总医院的研究人员进行了一项工作,旨在调查基因组成是否缓和了教育对健康的影响。

N Engl J Med:戒烟会变胖 抵消戒烟带来的健康益处?

戒烟可降低主要慢性疾病的风险,并延长预期寿命,但戒烟后戒烟者可能会出现相当大的增重。这种增重可能是由于食欲增加和能量消耗减少,可能会妨碍戒烟尝试,并可能通过增加心血管疾病和过早死亡的风险,来抵消戒烟对健康的益处。

Eur Respir J:早期哮喘发病能增加儿童肥胖风险么?

过去几十年当中,儿童哮喘和肥胖的并行发生促使了人们去探究肥胖是哮喘风险因子的研究。然而,哮喘在肥胖发生当中的作用却很少了解。最近,有研究人员调查了是否早期的哮喘发病和相关的症状与儿童时期发张为肥胖的风险相关。研究包括了21130名儿童,他们出生于1990年到2008年之间。研究人员对非肥胖儿童3-4岁时开始进行跟踪调查肥胖的发生情况,直到8岁。研究人员还对3-4岁的儿童进行了医生诊断哮喘、喘息和过

高血脂非胖人专属,高血脂认识的9大误区

心血管病关键在于预防和疾病的管理,重要性“无论怎么都不为过”,血胆固醇每升高1%,冠心病事件发生的危险性升高2%。由于城镇化和老龄化等因素,我国居民的生活方式明显变化,1989年时,我国男性居民食用胆固醇仅为100 mg/d,至2009年时已逼近300 mg/d;在1978年至1992年的15年间,北京居民红肉、鸡蛋和牛奶的消耗量增加了5倍。同期,体力活动也明显下降,10年间,我国男性总体力活动量

NEJM:研究揭示预防肥胖的关键时期

一项大型研究发现,大多数肥胖青少年在2~6岁的儿童早期体重增加最明显,之后体重增加速度减慢但仍在继续增加,导致青少年期肥胖程度更高。

JAMA Oncol:扎心了!8.5万年轻女性随访22年显示,女性肥胖与结直肠癌风险增加93%有关

来自华盛顿大学医学院的Yin Cao学者及其同事对85256名年龄在25岁-44岁之间的女性进行了22年的随访,探究体质指数(BMI)和结直肠癌风险之间的关系。结果发现,对于50岁以下的中青年群体,BMI≥30与结直肠癌风险增加93%有关!BMI每增加5个单位,与结直肠癌风险增加20%有关!

Baidu
map
Baidu
map
Baidu
map